# US 2024/0197708 A1 · Treatment of prodromal huntington disease

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0197708 A1
- Document ID: US20240197708A1
- Status: Published application
- Kind: A1
- Application number: 18/553,758
- Filed: 2022-04-14
- Published: 2024-06-20
- Earliest claimed: 2021-04-14
- Assignees: Prilenia Neurotherapeutics Ltd.
- Applicants: Prilenia Neurotherapeutics Ltd.
- Inventors: Michael HAYDEN; Michal GEVA
- Web page: https://patentgrep.com/patent/US20240197708A1

## CPC

- A61K 31/451: having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
- A61P 25/14: for treating abnormal movements, e.g. chorea, dyskinesia
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Disclosed herein are methods treating prodromal HD in a subject, wherein the subject has at least 36 CAG repeats in the huntingtin (Htt) gene, wherein the method comprises administering a composition comprising pridopidine or a pharmaceutically acceptable salt thereof.

## Claims

### Claim 1

A method of treating prodromal Huntington Disease (HD) in a subject who has at least 36 CAG repeats in the huntingtin (Htt) gene, wherein said method comprises administering a composition comprising pridopidine or a pharmaceutically acceptable salt thereof.

### Claim 2 (depends on 1)

The method of claim 1, wherein said prodromal HD subject has Unified Huntington's Disease Rating Scale-Total Functional Capacity (UHDRS-TFC) of 13.

### Claim 3 (depends on 1)

The method of claim 1, wherein said prodromal HD subject has a Diagnostic Confidence Level (DCL) of 1, 2 or 3.

### Claim 4 (depends on 1)

The method of claim 1, wherein said prodromal HD subject is characterized by impairment of motor functions comprising Total Motor Scale (TMS) with a score of between 5 and 10.

### Claim 5 (depends on 1)

The method of claim 1, wherein said prodromal HD subject has an IS ≥90%.

### Claim 6 (depends on 1)

The method of claim 1, wherein said prodromal HD subject is in Stage 1 or Stage 2 in the HD Integrated Staging System (HD-ISS).

### Claim 7 (depends on 1)

The method of claim 1, wherein said prodromal HD subject has a Symbol Digits Modality Score (SDMT) of between 40 and 60.

### Claim 8 (depends on 1)

The method of claim 1, wherein the method comprises administering pridopidine or a pharmaceutically acceptable salt between 10 mg/day-225 mg/day.

### Claim 9 (depends on 1)

The method of claim 1, wherein the composition comprises additional Compound 1:
or combination thereof; or pharmaceutically acceptable salts thereof.

### Claim 10 (depends on 9)

The method of claim 9, wherein Compound 1 or Compound 4 have a weight percentage of 0.001%-1.0% relative to pridopidine.

### Claim 11 (depends on 10)

The method of claim 10, wherein Compound 1 or Compound 4 have a weight percentage of 0.05%-0.5% relative to pridopidine.

### Claim 12 (depends on 9)

The method of claim 9, wherein Compound 1 or Compound 4 have a weight percentage of 0.05%-0.3% relative to pridopidine.

### Claim 13 (depends on 1)

The method of claim 1, wherein the pharmaceutically acceptable salt is hydrochloride, hydrobromide, hydroiodide, nitrate, sulfate, bisulfate, phosphate, acid phosphate, isonicotinate, acetate, lactate, salicylate, citrate, D,L-tartrate, L-tartarate, D-tartarate, pantothenate, bitartrate, ascorbate, succinate, hemisuccinate, maleate, gentisinate, gentisate, fumarate, gluconate, glucaronate, glycolate, saccharate, formate, besylate, benzoate, glutamate, malate, methanesulfonate, ethanesulfonate, benzensulfonate, p-toluenesulfonate, oxalate, tosylate, naphtalen-2-sulfate, pamoate (i.e., 1,1′-methylene-bis-(2-hydroxy-3-naphthoate)), perchlorateaconate,cinnamate's citrate, embonate, enantate, malonate, mandelate, phthalate, sorbate or stearate salt.

### Claim 14 (depends on 9)

The method of claim 9, wherein the pharmaceutically acceptable salt is hydrochloride, hydrobromide, hydroiodide, nitrate, sulfate, bisulfate, phosphate, acid phosphate, isonicotinate, acetate, lactate, salicylate, citrate, D,L-tartrate, L-tartarate, D-tartarate, pantothenate, bitartrate, ascorbate, succinate, hemisuccinate, maleate, gentisinate, gentisate, fumarate, gluconate, glucaronate, glycolate, saccharate, formate, besylate, benzoate, glutamate, malate, methanesulfonate, ethanesulfonate, benzensulfonate, p-toluenesulfonate, oxalate, tosylate, naphtalen-2-sulfate, pamoate (i.e., 1,1′-methylene-bis-(2-hydroxy-3-naphthoate)), perchlorateaconate, cinnamate's citrate, embonate, enantate, malonate, mandelate, phthalate, sorbate or stearate salt.

### Claim 15 (depends on 2)

The method of claim 2, wherein said prodromal HD subject is characterized by impairment of motor functions comprising Total Motor Scale (TMS) with a score of between 5 and 10.
